Map 2 Rounds Handicap: KOLESIE (-9.5) vs GenOne (+9.5)

Track live probability, outcome prices, volume, liquidity, and resolution details for Map 2 Rounds Handicap: KOLESIE (-9.5) vs GenOne (+9.5). The market currently shows a live probability of 0%, $55 in 24h volume.

Track live esports prediction markets focused on competitive gaming tournaments, team performance, championship events, and major esports forecasting trends.

This market is currently listed with an end date of Jun 17, 2026. Market timelines can change if the underlying event is postponed, rescheduled, or resolved early.

This market refers to the Counter-Strike match between KOLESIE and GenOne in the CCT Europe Series #4 Group Stage, initially scheduled for June 16 at 2:05PM ET. This market is decided solely by the round score of Map 2 of this match, and is independent of which team wins Map 2 or the overall match. This market will resolve to "KOLESIE" if KOLESIE wins Map 2 by 10 or more rounds, including any overtime (i.e. KOLESIE's round total on Map 2 exceeds GenOne's by 10 or more). Otherwise, this market will resolve to "GenOne". Map 2 must be played to completion, with a final round score determined by rounds actually played, for this market to resolve to a team. If Map 2 is completed in this way, the market resolves on that round score regardless of how the remainder of the match concludes (including any later forfeit, disqualification, walkover, or default). If Map 2 is not played at all, is not played to completion, or is decided by forfeit, disqualification, walkover, or default rather than by rounds played to a conclusion, this market will resolve 50-50. If the match is canceled, or is delayed beyond 7 days from the scheduled date without Map 2 being completed, this market will resolve 50-50. The resolution source for this market will be official information from https://hltv.org. However, if https://hltv.org has not published final results within 2 hours after the event's conclusion, a consensus of credible reporting may be used instead, including video evidence.